Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 4Phase 1/2 3Phase 3 1

Status

Completed 33Terminated 6Active not recruiting 5Withdrawn 4Not yet recruiting 4Unknown 1Recruiting 1

Sponsor Class

OTHER 3NIH 3

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 2Breast 2Lymphoid 1CNS 1

Conditions

Melanoma 2Triple Negative Breast Neoplasms 1Neuroma, Acoustic 1Neurofibromatosis 2 1Meningioma 1Lymphoma, Large B-Cell, Diffuse 1Glioma 1Ependymoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Terminated × AZD 6244 × Clear all
NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

OHSU Knight Cancer Institute

Phase 2 Terminated
24 enrolled 16 charts
Breast

Triple Negative Breast Neoplasms

NCT03095248 2025-04-22

SEL-TH-1601

Children's Hospital Medical Center, Cincinnati

Phase 2 Terminated
10 enrolled 9 charts
CNS

Ependymoma, Glioma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT00780676 2020-09-03

Personalized Treatment Selection for Metastatic Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
97 enrolled 7 charts
Breast

Breast Neoplasms

NCT01278615 2016-02-03

Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
16 enrolled 9 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01519427 2014-06-18

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

National Cancer Institute (NCI)

Phase 2 Terminated
2 enrolled 9 charts
Dermatologic

Melanoma

NCT01166126 2014-05-15

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

National Cancer Institute (NCI)

Phase 2 Terminated
4 enrolled 7 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡